CRL:NYE-Charles River Laboratories International Inc. (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 217.55

Change

-1.45 (-0.66)%

Market Cap

USD 3.40B

Volume

0.34M

Analyst Target

USD 238.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Charles River Laboratories International Inc provides research models and services required to enable in vivo drug discovery and development.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
TMO Thermo Fisher Scientific Inc

N/A

USD 219.83B
DHR Danaher Corporation

N/A

USD 191.36B
IQV IQVIA Holdings Inc

N/A

USD 39.94B
A Agilent Technologies Inc

N/A

USD 37.89B
MTD Mettler-Toledo International I..

N/A

USD 30.86B
WAT Waters Corporation

N/A

USD 17.83B
LH Laboratory Corporation of Amer..

N/A

USD 16.74B
DGX Quest Diagnostics Incorporated

N/A

USD 15.68B
RVTY Revvity Inc.

N/A

USD 13.69B
QGEN Qiagen NV

N/A

USD 9.95B

ETFs Containing CRL

JSMD Janus Henderson Small/Mid.. 2.75 % 0.50 %

N/A

USD 0.35B
HEAL:CA 2.65 % 0.00 %

N/A

N/A
SAEF Schwab Strategic Trust 2.45 % 0.00 %

N/A

USD 0.02B
XLVE:CA Mulvihill U.S. Health Car.. 1.86 % 0.00 %

N/A

CAD 7.08M
IS3V:XETRA iShares Global Inflation .. 0.63 % 0.00 %

N/A

USD 0.20B
GNRX 0.00 % 0.55 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.97% 21% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.97% 21% F 16% F
Trailing 12 Months  
Capital Gain 11.63% 54% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.63% 54% F 46% F
Trailing 5 Years  
Capital Gain 67.47% 64% D 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.47% 64% D 73% C
Average Annual (5 Year Horizon)  
Capital Gain 22.66% 100% F 86% B+
Dividend Return 22.66% 100% F 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.76% 8% B- 18% F
Risk Adjusted Return 42.94% 54% F 65% D
Market Capitalization 3.40B 31% F 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.50 92% 29%
Price/Book Ratio 3.46 54% 25%
Price / Cash Flow Ratio 16.80 69% 22%
Price/Free Cash Flow Ratio 14.75 69% 26%
Management Effectiveness  
Return on Equity 13.14% 54% 69%
Return on Invested Capital 8.66% 50% 60%
Return on Assets 4.95% 62% 72%
Debt to Equity Ratio 73.60% 23% 47%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.